Magrolimab + Azacitidine
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Sep 8, 2017 → Sep 5, 2023
NCT ID
NCT03248479About Magrolimab + Azacitidine
Magrolimab + Azacitidine is a phase 1 stage product being developed by Gilead Sciences for Hematological Malignancies. The current trial status is terminated. This product is registered under clinical trial identifier NCT03248479. Target conditions include Hematological Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03248479 | Phase 1 | Terminated |
Competing Products
20 competing products in Hematological Malignancies